[{"command":"openDialog","selector":"#drupal-modal","settings":null,"data":"\u003Cdiv id=\u0022republish_modal_form\u0022\u003E\u003Cform class=\u0022modal-form-example-modal-form ecl-form\u0022 data-drupal-selector=\u0022modal-form-example-modal-form\u0022 action=\u0022\/en\/article\/modal\/6868\u0022 method=\u0022post\u0022 id=\u0022modal-form-example-modal-form\u0022 accept-charset=\u0022UTF-8\u0022\u003E\u003Cp\u003EHorizon articles can be republished for free under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.\u003C\/p\u003E\n \u003Cp\u003EYou must give appropriate credit. We ask you to do this by:\u003Cbr \/\u003E\n 1) Using the original journalist\u0027s byline\u003Cbr \/\u003E\n 2) Linking back to our original story\u003Cbr \/\u003E\n 3) Using the following text in the footer: This article was originally published in \u003Ca href=\u0027#\u0027\u003EHorizon, the EU Research and Innovation magazine\u003C\/a\u003E\u003C\/p\u003E\n \u003Cp\u003ESee our full republication guidelines \u003Ca href=\u0027\/horizon-magazine\/republish-our-stories\u0027\u003Ehere\u003C\/a\u003E\u003C\/p\u003E\n \u003Cp\u003EHTML for this article, including the attribution and page view counter, is below:\u003C\/p\u003E\u003Cdiv class=\u0022js-form-item form-item js-form-type-textarea form-item-body-content js-form-item-body-content ecl-form-group ecl-form-group--text-area form-no-label ecl-u-mv-m\u0022\u003E\n \n\u003Cdiv\u003E\n \u003Ctextarea data-drupal-selector=\u0022edit-body-content\u0022 aria-describedby=\u0022edit-body-content--description\u0022 id=\u0022edit-body-content\u0022 name=\u0022body_content\u0022 rows=\u00225\u0022 cols=\u002260\u0022 class=\u0022form-textarea ecl-text-area\u0022\u003E\u003Ch2\u003EEurope is in danger of being out-innovated in regenerative medicine \u2013 Prof. Ton Rabelink\u003C\/h2\u003E\u003Cp\u003E\u003Cstrong\u003EWhy has stem cell research been so fraught with controversy?\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u2018A lot of medicine nowadays is not about curation, but trying to reduce progression or manage chronic diseases. When people have illnesses that are really debilitating or limit their lifespan, they become desperate to find a miracle cure. That is the sort of promise that comes with the stem cell story because it can restore function, it allows you to make new tissues, so people begin to ask: \u201cIf I have kidney disease, can I make a new kidney? If I have diabetes, can I make new beta cells? Can I mend my heart, basically, through this type of biology?\u201d\u003C\/p\u003E\u003Cp\u003E\u2018There\u0027s obviously a big selection bias, but if you have a positive result, then the preclinical data (from animal trials) are often very attractive. And even though it\u2019s still a long way to clinical application, some practitioners capitalise economically on the hope or despair of patients.\u003C\/p\u003E\u003Cp\u003E\u2018For example, in the United States little legislation is in place to regulate stem cell therapy,\u0026nbsp;(and it is not) a defined product. So any doctor can just open up a so-called stem cell clinic. They\u2019re using it for everything \u2014 hair growth, diabetes \u2014 and they create false hope.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EAt the same time, would you say that valid research in regenerative medicine is thriving?\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u2018Yes, it is becoming a very important theme in healthcare. And this is because of what I just told you about chronic disease. It\u2019s unsustainable to treat patients with three or four chronic diseases at the same time, with drugs that work only partially. Yet that is our current reality. We really need to create a paradigm shift, to target central mechanisms and capitalise on the endogenous returns of capacity of the body (the body\u2019s ability to heal itself) \u2014or reinstall this capacity.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003ELast year, you finished work on a project called STELLAR to look at how regenerative medicine can help people suffering from chronic kidney disease. What did you do?\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u2018Progressive chronic kidney disease is not only a clinical problem, but an economical one. Apart from intensive care and treatment, chronic kidney disease is our most expensive illness. Every dialysis patient costs about \u20ac80,000 per year and that\u2019s still a very poor treatment.\u003C\/p\u003E\u003Cp\u003E\u2018We wanted to increase the availability of organs for transplantation and to explore whether we could reduce chronic kidney disease. There is a small population of what are called mesenchymal\u0026nbsp;stromal cells\u0026nbsp;(MSCs)\u0026nbsp;in the bone marrow. In 2006, scientists at the Karolinska Institute (in Sweden) discovered that if you take a biopsy from the bone marrow, expand the cells and then reinfuse them, they have an immune suppressant and regulatory effect, and create a pro-regenerative environment. Experiments in animals showed they could retard the progression of kidney disease but the real trick is, can you bring this to a human population? Our group was among the first to do clinical trials using these cells in our hospitals.\u003C\/p\u003E\u003Cp\u003E\u2018Then \u2026 we did some experiments with discarded kidneys, which had been offered for transplantation but couldn\u0027t be used for technical reasons. We found that similar cells were present in the kidney itself, which would have additional benefits over those from the bone marrow \u2014 a next generation type of cell. We\u2019re starting a phase one study (to test doses and side effects in humans) with these kidney stromal cells. This will focus on revitalising and preserving organs for transplantation that otherwise would have ended up the garbage bin, thus increasing the number of donated organs available.\u003C\/p\u003E\u003Cp\u003E\u2018Finally, as part of Stellar, we had teamed up with the group of scientists in Australia, one of whom, Melissa Little, discovered that you can actually reprogramme cells and differentiate them into kidney tissue \u2014 something people hadn\u2019t realised was possible. The kidney is a very complicated organ with more than 15 different specialised cell types. But if you create the right growth factors, thereby mimicking the early steps in embryogenesis (embryo formation), it\u2019s like loading a software program on your computer, pressing the enter button and then have it start to run. Conceptually, this means that you can take a cell from a patient, reprogramme it into a pluripotent stem cell and then grow your own kidney tissue. It\u2019s still a long way from clinical application, of course, but it\u2019s the most imaginative piece of progress we\u2019ve made.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EIt sounds as though there\u2019s a lot of promise, but you\u2019ve also mentioned that it\u2019s important not to give people false hope. How well does Europe\u2019s regulatory system balance this?\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u2018The regulatory framework in Europe operates through the European Medicines Agency, EMA. You can give a patient cell therapy in a research setting. Alternatively, the product must get market authorisation, but has to go through the system as if it were a chemical drug, even though its biology is very different and some aspects of the process aren\u2019t relevant. The third possibility is to apply a hospital exemption, which is the way bone marrow transplants are being done right now.\u003C\/p\u003E\u003Cp\u003E\u2018But as we move towards real stem cell innovations, there is no good understanding of what the safety requirements should be. If we modify a cell genetically, there\u0027s always the fear that this may lead to future tumorigenesis, causing cancer. So how do you safeguard against that possibility? The EMA is looking at the right mechanisms to support the field.\u003C\/p\u003E\u003Cp\u003E\u2018It is very important that they do this because the regulatory landscape in the US and Japan has changed over the past two or three years to accommodate recent advances. For example, Japan has an early access programme for treatments that seem promising but are not yet proven to work. If they appear safe in say, 40 patients, then doctors can start applying them. The US has created the \u003Ca href=\u0022https:\/\/www.fda.gov\/RegulatoryInformation\/LawsEnforcedbyFDA\/SignificantAmendmentstotheFDCAct\/21stCenturyCuresAct\/default.htm\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003E21\u003Csup\u003Est\u003C\/sup\u003E Century Cures Act\u003C\/a\u003E that allows for clinical trials for stem cell therapies and fast-track access to market for those that appear effective.\u003C\/p\u003E\u003Cp\u003E\u003Cblockquote class=\u0022tw-text-center tw-text-blue tw-font-bold tw-text-2xl lg:tw-w-1\/2 tw-border-2 tw-border-blue tw-p-12 tw-my-8 lg:tw-m-12 lg:tw--ml-16 tw-float-left\u0022\u003E\n \u003Cspan class=\u0022tw-text-5xl tw-rotate-180\u0022\u003E\u201c\u003C\/span\u003E\n \u003Cp class=\u0022tw-font-serif tw-italic\u0022\u003E\u0026#039;As we move towards real stem cell innovations, there is no good understanding of what the safety requirements should be.\u0026#039;\u003C\/p\u003E\n \u003Cfooter\u003E\n \u003Ccite class=\u0022tw-not-italic tw-font-normal tw-text-sm tw-text-black\u0022\u003EProfessor Ton Rabelink, Leiden University, the Netherlands\u003C\/cite\u003E\n \u003C\/footer\u003E\n\u003C\/blockquote\u003E\n\u003C\/p\u003E\u003Cp\u003E\u2018The risk is that if we don\u2019t organise locally here in Europe, we\u2019ll end up having to buy these treatments from those countries. We\u2019ve \u003Ca href=\u0022https:\/\/www.newscientist.com\/article\/dn28454-gene-editing-saves-life-of-girl-dying-from-leukaemia-in-world-first\/\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003Ealready seen this\u003C\/a\u003E with genetically modified cells, so-called CAR cells, to attack tumours in leukaemia. The treatment works quite well but costs about \u20ac500,000 per patient.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EWhat else is needed to turn this type of research into actual treatments?\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u2018It\u0027s very interesting to look at what happens in the rest of the world. You really need ecosystems \u2014 academia, but also legislatures, manufacturing and, of course, finance. The US has huge ecosystems like \u003Ca href=\u0022https:\/\/www.cirm.ca.gov\/\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003ECIRM\u003C\/a\u003E, the California Institute for Regenerative Medicine, which was founded through taxpayers\u2019 money following a referendum, and invests about $250 million per year in this space.\u003C\/p\u003E\u003Cp\u003E\u2018The situation in Japan is even more remarkable. The early breakthroughs were made by a Japanese scientist so they consider regenerative medicine almost as their national invention. And, of course, Japan has an ageing population so the concept is very appealing. The government set up a planned economy around regenerative medicine and adapted its regulatory framework, putting national systems in place to oversee quality and safety and organising private-public collaborations, bringing together academic institutions and big pharma. Fujifilm, which was originally a photographic company, is devoting resources to stem cell research and using its film technology to make biomembranes.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EHow long does it usually take for advances in the lab to reach actual patients?\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u2018Right now, in Europe, it takes about 10 to 15 years between a first-in-men trial of the treatment and full clinical application. I think it\u2019s good to have a rigorous system \u2014 first, do no harm. We should not embark on dangerous adventures.\u003C\/p\u003E\u003Cp\u003E\u2018But I don\u2019t think it\u2019s still necessary to have such a long trajectory. We should create flexibility to accommodate scientific innovations. We could prepare these kinds of cells for clinical application in a period of 5 to 10 years instead of 10 to 15. That would be very meaningful for patients.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EThe research in this article was funded by the EU. If you liked this article, please consider sharing it on social media.\u003C\/em\u003E\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022http:\/\/bit.ly\/newsalertsignup\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003E\u003Cimg src=\u0022https:\/\/horizon-magazine.eu\/research-and-innovation\/sites\/default\/files\/hm\/news-alert-final.jpg\u0022 alt width=\u0022983\u0022 height=\u0022222\u0022\u003E\u003C\/a\u003E\u003C\/p\u003E\u003C\/textarea\u003E\n\u003C\/div\u003E\n\n \u003Cdiv id=\u0022edit-body-content--description\u0022 class=\u0022ecl-help-block description\u0022\u003E\n Please copy the above code and embed it onto your website to republish.\n \u003C\/div\u003E\n \u003C\/div\u003E\n\u003Cinput autocomplete=\u0022off\u0022 data-drupal-selector=\u0022form-okdgokv7grlqjfs-xnmmqpw0l8vlljxdn80zwiprfvq\u0022 type=\u0022hidden\u0022 name=\u0022form_build_id\u0022 value=\u0022form-OkDgOkV7gRlqJfs-xNMMQpw0l8vlLjxDN80ZWiPrfVQ\u0022 \/\u003E\n\u003Cinput data-drupal-selector=\u0022edit-modal-form-example-modal-form\u0022 type=\u0022hidden\u0022 name=\u0022form_id\u0022 value=\u0022modal_form_example_modal_form\u0022 \/\u003E\n\u003C\/form\u003E\n\u003C\/div\u003E","dialogOptions":{"width":"800","modal":true,"title":"Republish this content"}}]